TY - JOUR
T1 - Inhibition of TGFβ1 and TGFβ3 promotes hematopoiesis in Fanconi anemia
AU - Rodríguez, Alfredo
AU - Yang, Chunyu
AU - Furutani, Elissa
AU - García de Teresa, Benilde
AU - Velázquez, Martha
AU - Filiatrault, Jessica
AU - Sambel, Larissa A.
AU - Phan, Tin
AU - Flores-Guzmán, Patricia
AU - Sánchez, Silvia
AU - Monsiváis Orozco, Angélica
AU - Mayani, Héctor
AU - Bolukbasi, Ozge V.
AU - Färkkilä, Anniina
AU - Epperly, Michael
AU - Greenberger, Joel
AU - Shimamura, Akiko
AU - Frías, Sara
AU - Grompe, Markus
AU - Parmar, Kalindi
AU - D'Andrea, Alan D.
N1 - Publisher Copyright:
© 2020 ISEH – Society for Hematology and Stem Cells
PY - 2021/1
Y1 - 2021/1
N2 - Fanconi anemia (FA) is a chromosome instability syndrome with congenital abnormalities, cancer predisposition and bone marrow failure (BMF). Although hematopoietic stem and progenitor cell (HSPC) transplantation is the recommended therapy, new therapies are needed for FA patients without suitable donors. BMF in FA is caused, at least in part, by a hyperactive growth-suppressive transforming growth factor β (TGFβ) pathway, regulated by the TGFβ1, TGFβ2, and TGFβ3 ligands. Accordingly, the TGFβ pathway is an attractive therapeutic target for FA. While inhibition of TGFβ1 and TGFβ3 promotes blood cell expansion, inhibition of TGFβ2 is known to suppress hematopoiesis. Here, we report the effects of AVID200, a potent TGFβ1- and TGFβ3-specific inhibitor, on FA hematopoiesis. AVID200 promoted the survival of murine FA HSPCs in vitro. AVID200 also promoted in vitro the survival of human HSPCs from patients with FA, with the strongest effect in patients progressing to severe aplastic anemia or myelodysplastic syndrome (MDS). Previous studies have indicated that the toxic upregulation of the nonhomologous end-joining (NHEJ) pathway accounts, at least in part, for the poor growth of FA HSPCs. AVID200 downregulated the expression of NHEJ-related genes and reduced DNA damage in primary FA HSPC in vitro and in in vivo models. Collectively, AVID200 exhibits activity in FA mouse and human preclinical models. AVID200 may therefore provide a therapeutic approach to improving BMF in FA.
AB - Fanconi anemia (FA) is a chromosome instability syndrome with congenital abnormalities, cancer predisposition and bone marrow failure (BMF). Although hematopoietic stem and progenitor cell (HSPC) transplantation is the recommended therapy, new therapies are needed for FA patients without suitable donors. BMF in FA is caused, at least in part, by a hyperactive growth-suppressive transforming growth factor β (TGFβ) pathway, regulated by the TGFβ1, TGFβ2, and TGFβ3 ligands. Accordingly, the TGFβ pathway is an attractive therapeutic target for FA. While inhibition of TGFβ1 and TGFβ3 promotes blood cell expansion, inhibition of TGFβ2 is known to suppress hematopoiesis. Here, we report the effects of AVID200, a potent TGFβ1- and TGFβ3-specific inhibitor, on FA hematopoiesis. AVID200 promoted the survival of murine FA HSPCs in vitro. AVID200 also promoted in vitro the survival of human HSPCs from patients with FA, with the strongest effect in patients progressing to severe aplastic anemia or myelodysplastic syndrome (MDS). Previous studies have indicated that the toxic upregulation of the nonhomologous end-joining (NHEJ) pathway accounts, at least in part, for the poor growth of FA HSPCs. AVID200 downregulated the expression of NHEJ-related genes and reduced DNA damage in primary FA HSPC in vitro and in in vivo models. Collectively, AVID200 exhibits activity in FA mouse and human preclinical models. AVID200 may therefore provide a therapeutic approach to improving BMF in FA.
UR - http://www.scopus.com/inward/record.url?scp=85097098357&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85097098357&partnerID=8YFLogxK
U2 - 10.1016/j.exphem.2020.11.002
DO - 10.1016/j.exphem.2020.11.002
M3 - Article
C2 - 33166613
AN - SCOPUS:85097098357
SN - 0301-472X
VL - 93
SP - 70-84.e4
JO - Experimental hematology
JF - Experimental hematology
ER -